{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:50:12Z","timestamp":1790261412031,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI 126619"],"award-info":[{"award-number":["AI 126619"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI50410"],"award-info":[{"award-number":["AI50410"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HSN261200800001E"],"award-info":[{"award-number":["HSN261200800001E"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TR 002489"],"award-info":[{"award-number":["TR 002489"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Approaches to deplete persistent HIV infection are needed. We investigated the combined impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous dendritic cell immunotherapeutic, on the HIV reservoir. HIV+, stably treated participants in whom resting CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell-associated HIV RNA (rca-RNA) increased after VOR exposure\n                    <jats:italic>ex vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    received 4 doses of AGS-004 every 3 weeks, followed by VOR every 72\u2009hours for 30 days, and then the cycle repeated. Change in VOR-responsive host gene expression, HIV-specific T cell responses, low-level HIV viremia, rca-RNA, and the frequency of resting CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell infection (RCI) was measured at baseline and after each cycle. No serious treatment-related adverse events were observed among five participants. As predicted, VOR-responsive host genes responded uniformly to VOR dosing. Following cycles of AGS-004 and VOR, rca-RNA decreased significantly in only two participants, with a significant decrease in SCA observed in one of these participants. However, unlike other cohorts dosed with AGS-004, no uniform increase in HIV-specific immune responses following vaccination was observed. Finally, no reproducible decline of RCI, defined as a decrease of &gt;50%, was observed. AGS-004 and VOR were safe and well-tolerated, but no substantial impact on RCI was measured. In contrast to previous clinical data, AGS-004 did not induce HIV-specific immune responses greater than those measured at baseline. More efficacious antiviral immune interventions, perhaps paired with more effective latency reversal, must be developed to clear persistent HIV infection.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-61878-3","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T07:03:20Z","timestamp":1584687800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection"],"prefix":"10.1038","volume":"10","author":[{"given":"Cynthia L.","family":"Gay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann D.","family":"Kuruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3554-226X","authenticated-orcid":false,"given":"Shane D.","family":"Falcinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna A.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Reifeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Kirchherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan G.","family":"Dewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Allard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Stuelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Plachco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilu","family":"Goonetilleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"DeBenedette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Y.","family":"Tcherepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Nicolette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancie M.","family":"Archin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5714-0002","authenticated-orcid":false,"given":"David M.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"61878_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-virology-101416-041646","volume":"4","author":"U Mbonye","year":"2017","unstructured":"Mbonye, U. & Karn, J. The Molecular Basis for Human Immunodeficiency Virus Latency. Annu. Rev. Virol. 4, 261\u2013285 (2017).","journal-title":"Annu. Rev. Virol."},{"key":"61878_CR2","first-page":"229","volume":"90","author":"AW Turner","year":"2017","unstructured":"Turner, A. W. & Margolis, D. M. Chromatin Regulation and the Histone Code in HIV Latency. Yale J. Biol. Med. 90, 229\u2013243 (2017).","journal-title":"Yale J. Biol. Med."},{"key":"61878_CR3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482\u2013485 (2012).","journal-title":"Nature"},{"key":"61878_CR4","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1172\/JCI92684","volume":"127","author":"NM Archin","year":"2017","unstructured":"Archin, N. M. et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J. Clin. Invest. 127, 3126\u20133135 (2017).","journal-title":"J. Clin. Invest."},{"key":"61878_CR5","doi-asserted-by":"crossref","unstructured":"Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. Plos Pathog. 10 (2014).","DOI":"10.1371\/journal.ppat.1004473"},{"key":"61878_CR6","doi-asserted-by":"publisher","first-page":"70014","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. Lancet HIV 1, 70014\u201370011 (2014).","journal-title":"Lancet HIV"},{"key":"61878_CR7","doi-asserted-by":"crossref","unstructured":"Sogaard, O. S. et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. Plos Pathog. 11 (2015).","DOI":"10.1371\/journal.ppat.1005142"},{"key":"61878_CR8","doi-asserted-by":"crossref","unstructured":"Garrido, C. et al. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J. Virol. 92 (2018).","DOI":"10.1128\/JVI.00235-18"},{"key":"61878_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ebiom.2017.07.019","volume":"23","author":"JA Sung","year":"2017","unstructured":"Sung, J. A. et al. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells. EBioMedicine 23, 52\u201358 (2017).","journal-title":"EBioMedicine"},{"key":"61878_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/QAI.0000000000000926","volume":"72","author":"JM Jacobson","year":"2016","unstructured":"Jacobson, J. M. et al. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J. Acquir. Immune Defic. Syndr. 72, 31\u201338 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"61878_CR11","unstructured":"DeBenedette, M. et al. In Conference on Retroviruses and Opportunistic Infections. Boston, MA. (2014)."},{"key":"61878_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/QAI.0b013e3182a4b9ad","volume":"64","author":"MA Jenabian","year":"2013","unstructured":"Jenabian, M. A. et al. Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 64, 345\u2013350 (2013).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"61878_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/aid.2017.0071","volume":"34","author":"CL Gay","year":"2018","unstructured":"Gay, C. L. et al. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Res. Hum. Retroviruses 34, 111\u2013122 (2018).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"61878_CR14","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1097\/QAD.0000000000000839","volume":"29","author":"B Reardon","year":"2015","unstructured":"Reardon, B. et al. Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. AIDS 29, 2235\u20132244 (2015).","journal-title":"AIDS"},{"key":"61878_CR15","doi-asserted-by":"crossref","unstructured":"Crooks, A. M. et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. J. Infect. Dis. 15 (2015).","DOI":"10.1093\/infdis\/jiv218"},{"key":"61878_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAD.0000000000002112","volume":"33","author":"C Garrido","year":"2019","unstructured":"Garrido, C. et al. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. AIDS 33, 605\u2013613 (2019).","journal-title":"AIDS"},{"key":"61878_CR17","doi-asserted-by":"crossref","unstructured":"Sung, J. A. et al. Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. J. Infect. Dis. 13 (2015).","DOI":"10.1093\/infdis\/jiv022"},{"key":"61878_CR18","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1172\/JCI82314","volume":"125","author":"JA Sung","year":"2015","unstructured":"Sung, J. A. et al. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125, 4077\u20134090 (2015).","journal-title":"J. Clin. Invest."},{"key":"61878_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295\u20131300 (1997).","journal-title":"Science"},{"key":"61878_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/8394","volume":"5","author":"D Finzi","year":"1999","unstructured":"Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512\u2013517 (1999).","journal-title":"Nat. Med."},{"key":"61878_CR21","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193\u201313197 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61878_CR22","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrmicro3352","volume":"12","author":"NM Archin","year":"2014","unstructured":"Archin, N. M., Sung, J. M., Garrido, C., Soriano-Sarabia, N. & Margolis, D. M. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat. Rev. Microbiol. 12, 750\u2013764 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"61878_CR23","first-page":"11","volume":"11","author":"NM Archin","year":"2014","unstructured":"Archin, N. M. et al. HIV-1 Expression within Resting CD4 T-Cells Following Multiple Doses of Vorinostat. J. Infect. Dis. 11, 11 (2014).","journal-title":"J. Infect. Dis."},{"key":"61878_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep30749","volume":"6","author":"G Clutton","year":"2016","unstructured":"Clutton, G. et al. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function. Sci. Rep. 6, 30749 (2016).","journal-title":"Sci. Rep."},{"key":"61878_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/QAI.0000000000000852","volume":"71","author":"RT Gandhi","year":"2016","unstructured":"Gandhi, R. T. et al. Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J. Acquir. Immune Defic. Syndr. 71, 246\u2013253 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"61878_CR26","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/infdis\/jiv582","volume":"213","author":"BJ Macatangay","year":"2016","unstructured":"Macatangay, B. J. et al. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J. Infect. Dis. 213, 1400\u20131409 (2016).","journal-title":"J. Infect. Dis."},{"key":"61878_CR27","first-page":"166ra162","volume":"5","author":"F Garcia","year":"2013","unstructured":"Garcia, F. et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 5, 166ra162 (2013).","journal-title":"Sci. Transl. Med."},{"key":"61878_CR28","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1002\/eji.201344433","volume":"44","author":"Y Levy","year":"2014","unstructured":"Levy, Y. et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur. J. Immunol. 44, 2802\u20132810 (2014).","journal-title":"Eur. J. Immunol."},{"key":"61878_CR29","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.1.18938","volume":"17","author":"R Moura","year":"2014","unstructured":"Moura, R. et al. Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment. J. Int. AIDS Soc. 17, 18938 (2014).","journal-title":"J. Int. AIDS Soc."},{"key":"61878_CR30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1080\/21645515.2018.1463942","volume":"14","author":"EC Reis","year":"2018","unstructured":"Reis, E. C. et al. Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy. Hum. Vaccin. Immunother. 14, 1995\u20132002 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"61878_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.chom.2017.03.008","volume":"21","author":"RA Pollack","year":"2017","unstructured":"Pollack, R. A. et al. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe. 21, 494\u2013506.e494 (2017).","journal-title":"Cell Host Microbe."},{"key":"61878_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","volume":"155","author":"YC Ho","year":"2013","unstructured":"Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540\u2013551 (2013).","journal-title":"Cell"},{"key":"61878_CR33","doi-asserted-by":"publisher","first-page":"E2575","DOI":"10.1073\/pnas.1720665115","volume":"115","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proc. Natl. Acad. Sci. USA 115, E2575\u2013e2584 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61878_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/QAD.0000000000000974","volume":"30","author":"S Leth","year":"2016","unstructured":"Leth, S. et al. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. AIDS 30, 713\u2013721 (2016).","journal-title":"AIDS"},{"key":"61878_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"61878_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/QAD.0b013e32835b3e26","volume":"27","author":"N Beliakova-Bethell","year":"2013","unstructured":"Beliakova-Bethell, N. et al. Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS 27, 29\u201337 (2013).","journal-title":"AIDS"},{"key":"61878_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/QAD.0b013e3282fd6df4","volume":"22","author":"NM Archin","year":"2008","unstructured":"Archin, N. M. et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22, 1131\u20131135 (2008).","journal-title":"AIDS"},{"key":"61878_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2017.07.004","volume":"450","author":"IM Trumble","year":"2017","unstructured":"Trumble, I. M. et al. SLDAssay: A software package and web tool for analyzing limiting dilution assays. J. Immunol. Methods 450, 10\u201316 (2017).","journal-title":"J. Immunol. Methods"},{"key":"61878_CR39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1128\/JCM.32.3.732-739.1994","volume":"32","author":"LE Myers","year":"1994","unstructured":"Myers, L. E., McQuay, L. J. & Hollinger, F. B. Dilution assay statistics. J. Clin. Microbiol. 32, 732\u2013739 (1994).","journal-title":"J. Clin. Microbiol."},{"key":"61878_CR40","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/nprot.2008.108","volume":"3","author":"MS Malnati","year":"2008","unstructured":"Malnati, M. S. et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat. Protoc. 3, 1240\u20131248 (2008).","journal-title":"Nat. Protoc."},{"key":"61878_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jcv.2005.02.013","volume":"34","author":"K Israel-Ballard","year":"2005","unstructured":"Israel-Ballard, K. et al. TaqMan RT-PCR and VERSANT HIV-1 RNA 3.0 (bDNA) assay Quantification of HIV-1 RNA viral load in breast milk. J. Clin. Virol. 34, 253\u2013256 (2005).","journal-title":"J. Clin. Virol."},{"key":"61878_CR42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0684.2005.00128.x","volume":"34","author":"AN Cline","year":"2005","unstructured":"Cline, A. N., Bess, J. W., Piatak, M. Jr. & Lifson, J. D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34, 303\u2013312 (2005).","journal-title":"J. Med. Primatol."},{"key":"61878_CR43","doi-asserted-by":"publisher","first-page":"e116306","DOI":"10.1371\/journal.pone.0116306","volume":"9","author":"M Somsouk","year":"2014","unstructured":"Somsouk, M. et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. Plos One 9, e116306 (2014).","journal-title":"Plos One"},{"key":"61878_CR44","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1128\/JVI.80.10.4717-4728.2006","volume":"80","author":"N Goonetilleke","year":"2006","unstructured":"Goonetilleke, N. et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80, 4717\u20134728 (2006).","journal-title":"J. Virol."},{"key":"61878_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","volume":"3","author":"A Amin","year":"2015","unstructured":"Amin, A. et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J. Immunother Cancer 3, 14 (2015).","journal-title":"J. Immunother Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61878-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61878-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:17:44Z","timestamp":1670296664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61878-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61878"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61878-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J. Eron reports grants from Merck during the conduct of the study, personal fees from Merck, and personal fees from Gilead outside the submitted work. D.M. Margolis reports grants from N.I.H. during the conduct of the study, personal fees from Merck, and holds common stock in Gilead. C.L. Gay reports research grants from Viiv and Gilead during the conduct of this study. C.N. Nicolette, M. DeBenedette, I.Y. Tcherepanova, A. Gamble and A. Plachco were all fulltime employees of Argos Therapeutics at the time of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5134"}}